Poly Medicure Share Price Target 2026, 2027, 2028, 2029, 2030
- Market Cap
- ₹17,317 Cr
- Book Value
- ₹306.09
- Stock P/E
- 52.9
- Dividend Yield
- 0.20%
- ROE
- 11.2%
- ROCE
- 14.0%
- PEG Ratio
- 2.22
- EV/EBITDA
- 31.0
Fundamentals from Screener.in, as of 6 Aug 2026. Live price via Yahoo Finance.
Poly Medicure share price today
Poly Medicure Ltd (NSE: POLYMED) had a market capitalisation of ₹17,317 Cr and a recorded price of ₹1,693.80 in Gale’s internal 6 August 2026 snapshot. Its 52-week range was ₹1,191.10 to ₹2,121.80. The live market box above updates separately; the P/E, returns and operating figures below remain fixed to the snapshot date so a later quote is not mistaken for a refreshed financial analysis.
Poly Medicure is a rare listed Indian medical-device manufacturer with meaningful exports, regulatory capability and a widening product range. The internal record shows 19% five-year sales and profit growth, a 24% operating margin and modest debt. Yet FY26 consolidated profit declined as acquisitions, capacity and working capital expanded. The stock still traded at 52.9 times trailing earnings. The core question is therefore whether investment in renal care, cardiology, orthopaedics and global distribution can restore growth and capital returns before the valuation premium fades.
What Poly Medicure actually sells
Poly Medicure designs and manufactures disposable and single-use medical devices. Infusion products remain the largest revenue engine, including IV cannulas, catheters and related consumables. The company has expanded into renal products such as dialysers and dialysis consumables, blood-management products, respiratory and diagnostics categories, and more specialised cardiology and orthopaedic devices through internal development and acquisitions.
Medical devices are not one homogeneous market. A simple consumable may compete on cost, quality and distribution, while an implant or intervention device needs clinical evidence, physician confidence, approvals and training. Poly Medicure’s value lies in combining efficient Indian manufacturing with regulatory registrations and access to more than 125 countries. The same global footprint creates exposure to currency, product liability, quality systems and changing regulations.
| Platform | FY26 consolidated revenue / evidence | Strategic role |
|---|---|---|
| Infusion therapy | ₹997.3 Cr, down 1.5% | Established scale and cash-generation base |
| Renal care | ₹187.6 Cr, up 24.5% | Import substitution and recurring treatment demand |
| Other products | ₹690.4 Cr, up 36.3% | Diversification into faster-growing device categories |
| Domestic market | ₹581.7 Cr, up 19.6% | Hospital penetration and India manufacturing opportunity |
| International market | ₹1,280.2 Cr, up 9.3% | Regulatory moat, distribution and geographic diversification |
The portfolio now contains more than 225 devices, and management reports annual capacity of roughly 1.8 billion devices, 15 manufacturing plants across five countries and over 390 patents. These figures show breadth but do not by themselves establish profitability. Product launches need registration, commercial adoption and repeat demand. The relevant proof is gross profit and cash return after R&D, selling expense, clinician support and manufacturing investment.
FY26: revenue expanded while consolidated profit fell
Poly Medicure’s official FY26 presentation reported consolidated revenue of ₹1,875.3 Cr, up 12.3%. Gross margin improved to 68.2% from 66.7%, yet EBITDA was almost flat at ₹457.7 Cr and EBITDA margin declined to 24.4% from 27.5%. Profit after tax fell 5.3% to ₹320.7 Cr, with diluted EPS of ₹31.8 versus ₹34.1 in FY25.
The standalone business looked steadier: revenue grew 3.8% to ₹1,662.5 Cr, operating EBITDA was approximately flat at ₹446.1 Cr and PAT increased 1.4% to ₹336.0 Cr. Consolidated results include the early effects of acquired businesses, which added growth but also costs and lower margins. This separation is essential. Acquisitions can be strategically valuable while initially diluting profitability, but management must eventually demonstrate returns above the capital paid.
| FY26 measure | FY25 | FY26 | Interpretation |
|---|---|---|---|
| Consolidated revenue | ₹1,669.7 Cr | ₹1,875.3 Cr | Up 12.3%; acquisitions and new categories contributed |
| Consolidated gross margin | 66.7% | 68.2% | Product mix and manufacturing economics remained strong |
| Consolidated EBITDA | ₹458.6 Cr | ₹457.7 Cr | Essentially flat despite revenue growth |
| Consolidated EBITDA margin | 27.5% | 24.4% | Down 310 bps as expansion and acquired costs weighed |
| Consolidated PAT | ₹338.8 Cr | ₹320.7 Cr | Down 5.3%; growth did not reach the bottom line |
| Diluted EPS | ₹34.1 | ₹31.8 | Declined despite a larger revenue base |
Gross-margin improvement alongside EBITDA-margin compression implies that the issue was below gross profit—operating investment, integration and scale costs—not a collapse in product pricing. That can reverse if new platforms scale. It can also persist when the group continually adds complexity faster than it realises operating leverage. Investors need a bridge from revenue growth to consolidated free cash flow, not only an addressable-market narrative.
Infusion is the foundation, but concentration must decline carefully
Infusion therapy contributed a little over half of FY26 consolidated revenue and declined 1.5%. Poly Medicure describes itself as the world’s third-largest IV cannula producer, reflecting manufacturing scale and a wide customer base. Infusion consumables benefit from recurring hospital demand, but large tenders and distributors can be price-sensitive. Product quality is non-negotiable because a recall or regulatory restriction can affect multiple markets at once.
Mature infusion growth need not be rapid if it generates reliable cash to fund the next engines. The warning would be a sustained volume loss, pricing pressure or higher receivables used to protect reported revenue. The constructive outcome is stable infusion economics while renal and other specialised devices become a larger share of gross profit.
| Infusion-franchise test | Constructive signal | Risk signal |
|---|---|---|
| Volume | Stable or rising units across diverse markets | Tender loss or repeated distributor destocking |
| Pricing and mix | Gross margin holds through premium and safety products | Commodity pricing offsets volume gains |
| Quality | Clean inspections and low complaint trend | Recall, warning or market suspension |
| Cash conversion | Collections track shipment growth | Receivables rise to defend market share |
| Innovation | New devices use the same regulatory and distribution base | Launches add complexity without material sales |
The company needs to manage this transition without weakening its most dependable franchise. A fashionable new category does not compensate for eroding core quality. Conversely, a flat infusion year should not obscure faster structural growth elsewhere if margins and cash remain healthy.
Renal care is an import-substitution opportunity
Renal revenue grew 24.5% in FY26. Dialysis treatment is recurring, and India historically depended heavily on imported products. Poly Medicure’s indigenous dialysers and related consumables can benefit from local manufacturing, public healthcare expansion and hospital demand. Recurring procedures may provide better visibility than equipment sold only once.
The economic model still depends on clinical acceptance, yield, sterilisation quality, tender pricing and capacity utilisation. Government and large-hospital tenders can create scale but may bring longer payment cycles. Investors should separate product approvals from actual procedure-driven consumption and track how quickly the renal plant reaches efficient utilisation.
Renal can become a second meaningful pillar if it generates repeat consumable sales and does not require excessive credit. A large order announcement is weaker evidence than steady quarterly volume, gross margin and collections. The base scenario assumes diversification progresses but does not assume every domestic dialysis opportunity belongs to Poly Medicure.
Cardiology and orthopaedics raise both potential and complexity
Poly Medicure has expanded into higher-value intervention and implant categories, including drug-eluting stents, and consolidated the PendraCare and Citieffe acquisitions for part of FY26. PendraCare adds cardiology-related catheter capabilities; Citieffe brings orthopaedic trauma products. These markets can support deeper clinical relationships and higher revenue per procedure than standard consumables.
They also introduce different selling models. Physician training, clinical studies, tender access, country approvals and post-market surveillance become more important. Acquired manufacturing systems and cultures must be integrated without compromising quality. Goodwill rose materially in FY26, making acquisition returns an explicit part of the valuation case.
| Expansion area | Opportunity | Execution requirement |
|---|---|---|
| Drug-eluting stents | Larger Indian cardiology market and import substitution | Clinical evidence, physician adoption and price discipline |
| PendraCare | Specialised interventional-catheter portfolio | Cross-selling, registrations and integration |
| Citieffe | Orthopaedic trauma devices and European access | Surgeon relationships, quality systems and profitable scale |
| New-device launches | Thirty-five products launched in FY26 | Commercial revenue after development and approval costs |
| Global footprint | 125+ countries | Regulatory maintenance and diversified collections |
The correct question is not whether cardiology and orthopaedics have large addressable markets. It is whether Poly Medicure can earn an attractive return on the incremental capital required to enter them. Management’s official standalone ROIC measure declined from 25.6% to 21.4% during the investment phase. That remains respectable, but the consolidated internal ROCE is lower and should improve as acquisitions mature.
Working capital and acquisitions are the near-term pressure points
FY26 debtor days increased from 78 to 98, inventory days from 136 to 152, and the cash-conversion cycle from 183 to 215 days. Some inventory expansion may support a broader product range and more geographies. A longer cycle nevertheless locks up cash and increases expiry, obsolescence and collection risk.
Consolidated total debt rose from ₹177.6 Cr to ₹341.6 Cr. Cash and equivalents declined from ₹1,226.9 Cr to ₹842.2 Cr, while goodwill increased from ₹28.6 Cr to ₹273.8 Cr following acquisitions. The company remained in a net-cash position on these presentation figures, so financial stress is not the current issue. Capital deployment and integration quality are.
| Balance-sheet and working-capital item | FY25 | FY26 | Reading |
|---|---|---|---|
| Debtor days | 78 | 98 | Collections slowed as the group expanded |
| Inventory days | 136 | 152 | More cash tied up in products and inputs |
| Cash-conversion cycle | 183 days | 215 days | Material deterioration requiring reversal |
| Total debt | ₹177.6 Cr | ₹341.6 Cr | Higher after acquisitions and investment |
| Cash and equivalents | ₹1,226.9 Cr | ₹842.2 Cr | Still substantial, but reduced |
| Goodwill | ₹28.6 Cr | ₹273.8 Cr | Acquisition performance now matters more |
Medical-device inventory can require sterilisation, country-specific packaging and regulatory documentation, making the cycle structurally longer than many consumer businesses. That context explains part of the number but does not eliminate the risk. The clearest evidence of good execution would be rising acquired revenue and profit alongside stabilising working-capital days.
Growth, margins and capital efficiency
Gale’s internal snapshot shows sales and profit both compounding at 19% over five years. Over three years, sales grew 19% and profit 24%, a strong and relatively balanced record before the FY26 consolidated pause. The 24% operating margin demonstrates product and manufacturing quality. ROE of 11.2% and ROCE of 14% are much less exceptional because equity, cash and capital employed increased.
| Internal operating evidence | 6 Aug 2026 snapshot | Interpretation |
|---|---|---|
| Sales CAGR, 5 years | 19% | Durable expansion across markets and categories |
| Profit CAGR, 5 years | 19% | Earnings broadly matched revenue over a full period |
| Sales CAGR, 3 years | 19% | Recent top-line pace remained consistent |
| Profit CAGR, 3 years | 24% | Operating leverage before FY26 integration pressure |
| Operating margin | 24% | Strong device-manufacturing economics |
| ROCE | 14% | New capital must lift consolidated returns |
| ROE / five-year ROE | 11.2% / 14% | Current equity productivity is below its own history |
The gap between standalone ROIC and consolidated ROCE is worth following. Management’s ROIC definition focuses on invested operating capital and reported 21.4% for FY26, while Gale’s broader consolidated snapshot shows 14% ROCE. Both can be valid under different definitions. Investors should look for direction rather than choose the more flattering ratio: if acquisitions and new plants work, multiple return measures should improve.
Ownership and financial resilience
Promoter holding was 62.42% with no pledge in the internal snapshot. Debt/equity was 0.11, supporting financial flexibility. The dividend yield was only 0.20%, so the investment case depends on reinvested capital producing future earnings rather than current income.
| Governance and resilience check | Snapshot | Meaning |
|---|---|---|
| Promoter holding | 62.42% | Strong economic alignment, subject to normal governance scrutiny |
| Promoter pledge | 0% | No pledge overhang recorded |
| Debt/equity | 0.11 | Low accounting leverage despite higher FY26 debt |
| Book value per share | ₹306.09 | Capital base must earn better returns over time |
| Dividend yield | 0.20% | Most expected value depends on execution and compounding |
Quality systems, related-party dealings, acquisition accounting and capital allocation are more relevant than promoter ownership alone. A device maker’s reputation can change quickly after a compliance failure, so audit and regulatory disclosures deserve the same attention as revenue.
The numbers
| Metric | Internal 6 Aug 2026 snapshot |
|---|---|
| Market capitalisation | ₹17,317 Cr |
| Snapshot price | ₹1,693.80 |
| P/E · price/book | 52.9× · 5.58× |
| PEG · EV/EBITDA | 2.22 · 31.0× |
| ROE · ROCE | 11.2% · 14.0% |
| Operating margin | 24% |
| Debt/equity | 0.11 |
| EPS (TTM) | ₹32.29 |
| Book value per share | ₹306.09 |
| 52-week range | ₹1,191.10 – ₹2,121.80 |
Valuation: a quality premium needs renewed earnings growth
The snapshot P/E of 52.9 times, price/book of 5.58 times and EV/EBITDA of 31 times reflect confidence in the medical-device platform. Those multiples are difficult to support indefinitely with an 11.2% ROE and a year of declining consolidated profit. PEG of 2.22 also implies the price is high relative to the historical earnings pace, although acquisitions and a temporary margin dip can distort that comparison.
For a device manufacturer, P/E should be combined with EV/EBITDA, ROIC and cash conversion. High gross margins are attractive only when regulatory, selling, R&D and working-capital costs still leave durable free cash. The target model uses the internal TTM EPS of ₹32.29 dated 6 August 2026, compounds it for the 147 days remaining to the first year-end and one full year thereafter, applies the stated exit P/E and rounds each annual output to the nearest ₹5. It does not assume the present multiple persists automatically.
| Scenario | EPS growth assumption | Exit P/E | Business interpretation |
|---|---|---|---|
| Bear | 10% | 32× | Infusion stays soft, integration is slow and the premium compresses |
| Base | 17% | 43× | Renal and other devices scale while margins gradually recover |
| Bull | 24% | 55× | New categories, acquisitions and global distribution execute cleanly |
Poly Medicure share price target 2026 to 2030
The following table is a scenario map, not a forecast that the share price will move smoothly. The same audited and internal evidence can support different outcomes depending on margin recovery, device adoption, acquisition returns and the market’s willingness to pay for growth.
Scenario warning: clinical adoption, regulation, recalls, currency, tender pricing, acquisition integration, working capital and valuation multiples may differ from these assumptions. The outputs are not guaranteed returns or personalised advice.
What would change the thesis
The case would strengthen if consolidated EBITDA margin recovered, debtor and inventory days declined, renal maintained procedure-driven growth and acquired cardiology or orthopaedic products generated profitable repeat sales. Improvement in consolidated ROCE would tie those operating wins to shareholder value.
The case would weaken after a quality or regulatory event, sustained infusion-market loss, worsening receivables, acquisition impairment or repeated capital spending without utilisation. Gross-margin strength alone would not compensate for operating costs and cash absorption.
| Review item | FY26 signal | Evidence required next |
|---|---|---|
| Consolidated EBITDA margin | Fell despite higher gross margin | Operating leverage as acquired businesses scale |
| Cash-conversion cycle | Rose to 215 days | Better collections and inventory productivity |
| Renal revenue | Grew 24.5% | Repeat consumable demand with healthy tender terms |
| Infusion revenue | Declined modestly | Stabilisation without margin sacrifice |
| Acquisition returns | Goodwill and complexity increased | Segment profit, cash and cross-selling milestones |
| ROCE / ROIC | Lower during investment phase | Improvement across consistent definitions |
Should you buy Poly Medicure at the current price?
Poly Medicure has a differentiated device franchise, global regulatory reach and credible growth avenues. The dated valuation still assumes that the FY26 margin and profit pressure is temporary. Investors should seek evidence from cash conversion and acquisition economics rather than treating medical-device demand as sufficient on its own.
Existing holders can monitor whether capital returns recover as new assets mature. New investors should allow for both operating and multiple risk, especially after a premium valuation. Gale’s signed-in panel provides its current classification, and paid members can access the accumulation band. Position sizing, healthcare exposure and personal suitability require a separate decision.
FAQ
What is the Poly Medicure share price target for 2030?
The signed-in table displays bear, base and bull outcomes from 2026 to 2030. They are calculated from the published EPS-growth and exit-P/E assumptions, not presented as one certain target.
Why did Poly Medicure’s FY26 profit decline despite revenue growth?
Consolidated gross margin improved, but operating costs and acquisition integration reduced EBITDA margin. Profit also reflected a larger consolidated platform, so investors should track whether scale restores operating leverage.
What is Poly Medicure’s biggest business segment?
Infusion therapy remains the largest category. Renal care and other devices grew faster in FY26, which can diversify the company if those products earn attractive cash returns.
Why is the cash-conversion cycle important?
Devices may require long production, sterilisation, registration and distribution cycles. Rising inventory and debtor days still consume cash and can increase collection or obsolescence risk, making them central to earnings quality.
What is the main risk to the valuation model?
Margin recovery and acquisition returns may take longer than assumed, while a quality or regulatory event could damage growth and the P/E multiple together. Premium valuation increases the cost of disappointment.
When are Poly Medicure’s next results?
See Gale’s results calendar and verify the date through Poly Medicure’s exchange announcement. Official filings should be used when schedules differ.
Related research
- Rainbow Children’s Medicare share price target
- Dr Lal PathLabs share price target
- Kovai Medical Center share price target
Sources and methodology
- Poly Medicure FY26 investor presentation filed with NSE and FY26 audited results filing.
- Poly Medicure financial-results archive for company-hosted period filings.
- Screener.in consolidated financials, captured in Gale’s approved internal research snapshot on 6 August 2026.
Period labels are preserved: FY26 presentation figures are not mixed with the later TTM internal snapshot. Live quote data is indicative and maintained separately.
This article is research and education, not personalised investment advice. Gale is not a SEBI-registered investment adviser. Price targets are scenario arithmetic, not promises. Do your own research and consult a registered adviser before acting.